Chiara Castelli
  • Department of Experimental Oncology and Molecular Medicine, Unit of Immunotherapy of Human Tumors, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy
Research fields
  • Cancer biology
Personal information


Ph.D in Biological Science, University of Milan, Italy, 1982

Current position

Staff scientist, Reseach Department, IRCCS Istitut Nazioanle dei Tumori Milano, Italy


  1. Tazzari, M., Indio, V., Vergani, B., De Cecco, L., Rini, F., Negri, T., Camisaschi, C., Fiore, M., Stacchiotti, S., Dagrada, G. P., Casali, P. G., Gronchi, A., Astolfi, A., Pantaleo, M. A., Villa, A., Lombardo, C., Arienti, F., Pilotti, S., Rivoltini, L. and Castelli, C. (2017). Adaptive Immunity in Fibrosarcomatous Dermatofibrosarcoma Protuberans and Response to Imatinib Treatment. J Invest Dermatol 137(2): 484-493.
  2. Camisaschi, C., Vallacchi, V., Vergani, E., Tazzari, M., Ferro, S., Tuccitto, A., Kuchuk, O., Shahaj, E., Sulsenti, R., Castelli, C., Rodolfo, M., Rivoltini, L. and Huber, V. (2016). Targeting Immune Regulatory Networks to Counteract Immune Suppression in Cancer. Vaccines (Basel) 4(4).
  3. Tuccitto, A., Tazzari, M., Beretta, V., Rini, F., Miranda, C., Greco, A., Santinami, M., Patuzzo, R., Vergani, B., Villa, A., Manenti, G., Cleris, L., Giardiello, D., Alison, M., Rivoltini, L., Castelli, C. and Perego, M. (2016). Immunomodulatory Factors Control the Fate of Melanoma Tumor Initiating Cells. Stem Cells 34(10): 2449-2460.
  4. Stacchiotti, S., Astolfi, A., Gronchi, A., Fontana, A., Pantaleo, M. A., Negri, T., Brenca, M., Tazzari, M., Urbini, M., Indio, V., Colombo, C., Radaelli, S., Brich, S., Dei Tos, A. P., Casali, P. G., Castelli, C., Dagrada, G. P., Pilotti, S. and Maestro, R. (2016). Evolution of Dermatofibrosarcoma Protuberans to DFSP-Derived Fibrosarcoma: An Event Marked by Epithelial-Mesenchymal Transition-like Process and 22q Loss. Mol Cancer Res 14(9): 820-829.
  5. Spagnuolo, R. D., Brich, S., Bozzi, F., Conca, E., Castelli, C., Tazzari, M., Maestro, R., Brenca, M., Gualeni, A. V., Gloghini, A., Stacchiotti, S., Pierotti, M. A., Pilotti, S. and Negri, T. (2016). Sunitinib-induced morpho-functional changes and drug effectiveness in malignant solitary fibrous tumours. Oncotarget 7(29): 45015-45026.
  6. Stacchiotti, S., Pantaleo, M. A., Negri, T., Astolfi, A., Tazzari, M., Dagrada, G. P., Urbini, M., Indio, V., Maestro, R., Gronchi, A., Fiore, M., Dei Tos, A. P., Conca, E., Palassini, E., Vincenzi, B., Grosso, F., Pilotti, S., Castelli, C. and Casali, P. G. (2016). Efficacy and Biological Activity of Imatinib in Metastatic Dermatofibrosarcoma Protuberans (DFSP). Clin Cancer Res 22(4): 837-846.
  7. Tazzari, M., Palassini, E., Vergani, B., Villa, A., Rini, F., Negri, T., Colombo, C., Crippa, F., Morosi, C., Casali, P. G., Pilotti, S., Stacchiotti, S., Rivoltini, L. and Castelli, C. (2015). Melan-A/MART-1 immunity in a EWS-ATF1 translocated clear cell sarcoma patient treated with sunitinib: a case report. BMC Cancer 15: 58.
  8. Castelli, C., Rivoltini, L., Rodolfo, M., Tazzari, M., Belgiovine, C. and Allavena, P. (2015). Modulation of the myeloid compartment of the immune system by angiogenic- and kinase inhibitor-targeted anti-cancer therapies. Cancer Immunol Immunother 64(1): 83-89.
  9. Castelli, C., Triebel, F., Rivoltini, L. and Camisaschi, C. (2014). Lymphocyte activation gene-3 (LAG-3, CD223) in plasmacytoid dendritic cells (pDCs): a molecular target for the restoration of active antitumor immunity. Oncoimmunology 3(11): e967146.
  10. Tazzari, M., Negri, T., Rini, F., Vergani, B., Huber, V., Villa, A., Dagrada, P., Colombo, C., Fiore, M., Gronchi, A., Stacchiotti, S., Casali, P. G., Pilotti, S., Rivoltini, L. and Castelli, C. (2014). Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy. Br J Cancer 111(7): 1350-1362.
  11. Camisaschi, C., De Filippo, A., Beretta, V., Vergani, B., Villa, A., Vergani, E., Santinami, M., Cabras, A. D., Arienti, F., Triebel, F., Rodolfo, M., Rivoltini, L. and Castelli, C. (2014). Alternative activation of human plasmacytoid DCs in vitro and in melanoma lesions: involvement of LAG-3. J Invest Dermatol 134(7): 1893-1902.
  12. Camisaschi, C., Tazzari, M., Rivoltini, L. and Castelli, C. (2014). Monitoring the frequency and function of regulatory T cells and summary of the approaches currently used to inhibit regulatory T cells in cancer patients. Methods Mol Biol 1139: 201-221.
  13. Castelli, C., Tazzari, M., Negri, T., Vergani, B., Rivoltini, L., Stacchiotti, S. and Pilotti, S. (2013). Structured myeloid cells and anti-angiogenic therapy in alveolar soft part sarcoma. J Transl Med 11: 237.
  14. Camisaschi, C., Filipazzi, P., Tazzari, M., Casati, C., Beretta, V., Pilla, L., Patuzzo, R., Maurichi, A., Cova, A., Maio, M., Chiarion-Sileni, V., Tragni, G., Santinami, M., Vergani, B., Villa, A., Berti, E., Umansky, L., Beckhove, P., Umansky, V., Parmiani, G., Rivoltini, L. and Castelli, C. (2013). Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response. Cancer Immunol Immunother 62(5): 897-908.
  15. Filipazzi, P., Pilla, L., Mariani, L., Patuzzo, R., Castelli, C., Camisaschi, C., Maurichi, A., Cova, A., Rigamonti, G., Giardino, F., Di Florio, A., Asioli, M., Frati, P., Sovena, G., Squarcina, P., Maio, M., Danielli, R., Chiarion-Sileni, V., Villa, A., Lombardo, C., Tragni, G., Santinami, M., Parmiani, G. and Rivoltini, L. (2012). Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptides. Clin Cancer Res 18(23): 6485-6496.
We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.